v3.26.1
Stock-Based Compensation (Tables)
3 Months Ended
Mar. 31, 2026
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock Option Granted

During the three months ended March 31, 2026 and 2025, the Company granted options to purchase the number of shares of the Company’s common stock set forth in the table below (in thousands):

 

   2026   2025 
   Three months ended March 31, 
   2026   2025 
Stock options granted   199    122 
Schedule of Weighted-Average Assumptions Used for Stock Options Granted

The following weighted-average assumptions were used for stock options granted during the three months ended March 31, 2026 and 2025:

 

   2026   2025 
   Three months ended March 31, 
   2026   2025 
Weighted average risk-free rate   3.96%   4.42%
Weighted average volatility   123.21%   116.69%
Dividend yield   0.00%   0.00%
Expected term   8.82 years    5.98 years 
Schedule of Weighted Average Grant-date Fair Value of Stock Options

The per-share weighted average grant-date fair value of stock options granted during the three months ended March 31, 2026 and 2025 were as follows:

 

   2026   2025 
   Three months ended March 31, 
   2026   2025 
Weighted average grant date fair value  $0.39   $4.32 
Schedule of Stock-based Compensation Expense

For the three months ended March 31, 2026 and 2025, the Company recognized stock-based compensation expense as follows (in thousands):

 

   2026   2025 
   Three months ended March 31, 
   2026   2025 
Research and development  $13   $16 
General and administrative   295    486 
Total  $308   $502